HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pera, M. Articles by Deschamps, C. Search for Related Content PubMed PubMed Citation Articles by Pera, M. Articles by Deschamps, C.

The Annals of Thoracic Surgery, Vol 56, 1191-1197, Copyright © 1993 by The Society of Thoracic Surgeons

ARTICLES

Barrett's disease: pathophysiology of metaplasia and adenocarcinoma

M Pera, VF Trastek, PC Pairolero, A Cardesa, MS Allen and C Deschamps
Department of Surgery, Mayo Clinic, Rochester, MN 55905.

Peptic ulceration arising in the lower esophagus lined by columnar epithelium was described in detail by Tileston in 1906. Although this concept was challenged in 1950 by Barrett, experimental and clinical evidence has now conclusively demonstrated that Barrett's metaplasia is an acquired condition and is a consequence of chronic reflux of gastric or duodenal contents or both. Current concepts suggest that unknown trophic factors present in these secretions stimulate proliferation of multipotential reserve cells located in the esophageal submucosal glands resulting in columnar metaplasia of the normal squamous epithelium with subsequent potential for malignant degeneration. Today, numerous patients are affected by reflux esophagitis, a lesser number by Barrett's metaplasia, and a smaller but ever-enlarging group by adenocarcinoma. Although high-grade dysplasia is considered a precursor to invasive adenocarcinoma, detection of this abnormal mucosa remains controversial and currently requires esophagoscopy with biopsy. Epithelial markers, such as increased activity of mucosal ornithine decarboxylase, sulfomucin production, nuclear DNA aneuploidy, and recently molecular analysis, have also been proposed to identify those paitents at increased risk for malignant degeneration. As more is learned about the pathogenesis of Barrett's disease, perhaps these cancers can ultimately be prevented.

This article has been cited by other articles:

				Y. Xu, F. M. Selaru, J. Yin, T. T. Zou, V. Shustova, Y. Mori, F. Sato, T. C. Liu, A. Olaru, S. Wang, et al. Artificial Neural Networks and Gene Filtering Distinguish Between Global Gene Expression Profiles of Barrett's Esophagus and Esophageal Cancer Cancer Res., June 1, 2002; 62(12): 3493 - 3497. [Abstract] [Full Text] [PDF]

				A. G. Little Barrett's Esophagus Ann. Thorac. Surg., July 1, 1996; 62(1): 315 - 315. [Full Text]

				M. L. McDonald, V. F. Trastek, M. S. Allen, C. Deschamps, and P. C. Pairolero BARRETT'S ESOPHAGUS: DOES AN ANTIREFLUX PROCEDURE REDUCE THE NEED FOR ENDOSCOPIC SURVEILLANCE? J. Thorac. Cardiovasc. Surg., June 1, 1996; 111(6): 1135 - 1140. [Abstract] [Full Text]